for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Agios Pharmaceuticals Inc

AGIO.OQ

Latest Trade

44.25USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

28.43

 - 

68.92

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
44.25
Open
--
Volume
--
3M AVG Volume
18.65
Today's High
--
Today's Low
--
52 Week High
68.92
52 Week Low
28.43
Shares Out (MIL)
67.13
Market Cap (MIL)
2,817.35
Forward P/E
-5.99
Dividend (Yield %)
--

Next Event

Q4 2019 Agios Pharmaceuticals Inc Earnings Release

Latest Developments

More

Agios Presents Updated Data For Mitapivat From Extension Phase Of Drive PK Study In Patients With Pyruvate Kinase Deficiency

Agios Pharmaceuticals Establishes Proof-Of-Concept For Mitapivat In Non-Transfusion-Dependent Thalassemia Based On Preliminary Phase 2 Results

Agios Announces Pricing Of $256 Million Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

Industry

Biotechnology & Drugs

Contact Info

88 Sidney St

+1.617.6498600

http://www.agios.com/

Executive Leadership

David P. Schenkein

Executive Chairman of the Board

Jacqualyn A. Fouse

Chief Executive Officer, Director

Andrew Hirsch

Chief Financial Officer

Orlando Oliveira

Senior Vice President, General Manager, International

Darrin Miles

Senior Vice President, U.S. Commercial and Global Marketing

Key Stats

1.85 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.0K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-5.070

2017

-6.750

2018

-6.030

2019(E)

-7.012
Price To Earnings (TTM)
--
Price To Sales (TTM)
25.05
Price To Book (MRQ)
5.51
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-55.28
Return on Equity (TTM)
-49.26

Latest News

Latest News

Agios names former Celgene executive Jacqualyn Fouse as next CEO

Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

Agios names former Celgene executive Jacqualyn Fouse as next CEO

Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

Agios Pharmaceuticals leukemia drug gets U.S. approval

Agios Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration approved its treatment for a type of leukemia, the first targeted drug for patients with a specific genetic mutation.

FDA approves Agios Pharmaceuticals leukemia drug

Agios Pharmaceuticals Inc said on Friday its oral drug to treat a type of leukemia was approved by the U.S. health regulator.

BRIEF-Agios Qtrly Loss Per Share $1.63

* AGIOS PROVIDES BUSINESS UPDATE ON DISCOVERY RESEARCH STRATEGY AND PIPELINE, PROGRESS ON CLINICAL PROGRAMS, COMMERCIAL LAUNCH PREPARATIONS AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AT INVESTOR DAY

BRIEF-Agios Says First Patient Dosed In Lymphoma Study

* AGIOS ANNOUNCES FIRST PATIENT DOSED WITH MAT2A INHIBITOR AG-270 IN PHASE 1 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH AN MTAP DELETION Source text for Eikon: Further company coverage:

BRIEF-Agios Reports Qtrly Loss Per Share $1.81

* AGIOS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Agios sizes up funding needs

Agios Pharmaceuticals pivoted from industry conferences to the capital markets, securing US$425m in a follow-on stock sale that meets its funding needs for the year.

BRIEF-Agios prices offering of 7.09 mln shares at $67 per share

* AGIOS ANNOUNCES PRICING OF $475 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Agios Announces Proposed Offering Of Common Stock

* SAYS IT IS OFFERING TO SELL UP TO $400 MILLION OF ITS COMMON STOCK IN A PUBLIC OFFERING

BRIEF-Agios Outlines Key 2018 Priorities Expanding Clinical And Research Programs To Drive Long Term Value

* AGIOS OUTLINES KEY 2018 PRIORITIES EXPANDING CLINICAL AND RESEARCH PROGRAMS TO DRIVE LONG TERM VALUE

BRIEF-Agios Submits New Drug Application To The FDA For Ivosidenib

* AGIOS SUBMITS NEW DRUG APPLICATION TO THE FDA FOR IVOSIDENIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY AML AND AN IDH1 MUTATION

BRIEF-Agios Pharmaceuticals Presents New Safety Data From Study on Leukemia Drug

* PRESENTS NEW SAFETY DATA FROM PHASE 1 EXPANSION STUDY EVALUATING ORAL IVOSIDENIB IN PATIENTS WITH R/R AML AND IDH1 MUTATION

Promising responses seen with Agios leukemia drug in study

Nearly a third of patients with an advanced form of a fast-progressing leukemia who carry a specific genetic mutation experienced a complete or near complete response to an experimental Agios Pharmaceuticals drug, according to data from an early stage trial released on Monday...

BRIEF-Agios Pharmaceuticals Files For Potential Mixed Shelf Offering

* AGIOS PHARMACEUTICALS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2yOMDeC) Further company coverage:

BRIEF-Agios presents updated phase 1 data from dose expansion cohort of ivosidenib

* Agios presents updated phase 1 data from dose expansion cohort of ivosidenib (AG-120) in patients with IDH1 mutant positive glioma

BRIEF-Agios reports Q3 revenue $11.4 million

* Agios Pharmaceuticals Inc - Qtrly net loss per share $1.59 Source text for Eikon: Further company coverage:

BRIEF-Agios posts Q2 loss per share $1.78

* Agios Pharmaceuticals Inc - collaboration revenue was $11.3 million for quarter ended June 30, 2017, compared to $7.0 million for comparable period in 2016

BRIEF-Agios Pharma says FDA approves Idhifa for treating relapsed/refractory Acute Myeloid Leukemia

* FDA grants approval of Idhifa, the first oral targeted therapy for adult patients with relapsed/refractory acute myeloid leukemia and an IDH2 mutation Source text for Eikon: Further company coverage:

FDA approves leukemia treatment developed by Celgene, Agios

The U.S. Food and Drug Administration (FDA) on Tuesday approved Celgene Corp and Agios Pharmaceuticals Inc's treatment for acute myeloid leukemia (AML) patients with a specific genetic mutation.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up